Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
26890 | 199 | 22.5 | 56% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | NABUMETONE | Author keyword | 41 | 52% | 28% | 56 |
2 | 6 METHOXY 2 NAPHTHYLACETIC ACID | Author keyword | 7 | 67% | 3% | 6 |
3 | 6MNA | Author keyword | 1 | 100% | 1% | 2 |
4 | ANTIPYRETIC ACTION | Author keyword | 1 | 50% | 1% | 1 |
5 | APCI MS AND ESI MS DETECTION | Author keyword | 1 | 50% | 1% | 1 |
6 | PROGRAM MORFOL | Address | 1 | 50% | 1% | 1 |
7 | RENAL PROSTAGLANDIN | Author keyword | 1 | 50% | 1% | 1 |
8 | SIDDHA FORMULATION | Author keyword | 1 | 50% | 1% | 1 |
9 | INTERNAL MED RHEUMATOL MED | Address | 0 | 33% | 1% | 1 |
10 | AREA UNDER CURVE METHOD | Author keyword | 0 | 25% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | 6 METHOXY 2 NAPHTHYLACETIC ACID | 26 | 87% | 7% | 13 |
2 | COMPARING NABUMETONE | 4 | 75% | 2% | 3 |
3 | PRINCIPAL ACTIVE METABOLITE | 3 | 100% | 2% | 3 |
4 | RAT GASTRIC MUCOSAL | 3 | 100% | 2% | 3 |
5 | URINARY PROSTAGLANDIN EXCRETION | 2 | 67% | 1% | 2 |
6 | NABUMETONE | 2 | 16% | 5% | 9 |
7 | GASTROSCOPIC EVALUATION | 1 | 50% | 1% | 1 |
8 | ANTIINFLAMMATORY DRUG NABUMETONE | 0 | 33% | 1% | 1 |
9 | IBUPROFEN PLUS MISOPROSTOL | 0 | 33% | 1% | 1 |
10 | TENIDAP SODIUM | 0 | 33% | 1% | 1 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
NABUMETONE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN RHEUMATIC DISEASES | 1988 | 36 | 40 | 100% |
Clinical pharmacokinetics of nabumetone - The dawn of selective cyclo-oxygenase-2 inhibition? | 1997 | 13 | 30 | 60% |
Nabumetone - Therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis | 2004 | 26 | 164 | 21% |
Safety of the nonselective NSAID nabumetone - Focus on gastrointestinal tolerability | 2008 | 5 | 73 | 21% |
Features and properties of nabumetone | 2000 | 2 | 39 | 54% |
NSAID gastroenteropathy; Past, present and future | 1996 | 17 | 71 | 7% |
Dosing of antirheumatic drugs in renal disease and dialysis | 2004 | 8 | 91 | 5% |
Contribution of arthroscopy and magnetic resonance imaging to the evaluation of painful knee osteoarthritis | 2000 | 4 | 15 | 7% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PROGRAM MORFOL | 1 | 50% | 0.5% | 1 |
2 | INTERNAL MED RHEUMATOL MED | 0 | 33% | 0.5% | 1 |
3 | BIOL MED MBC 0365 | 0 | 20% | 0.5% | 1 |
4 | MED INTESTINAL DIS UNIT | 0 | 20% | 0.5% | 1 |
5 | MED RHEUMAT DIS | 0 | 17% | 0.5% | 1 |
6 | FARMOVS CLIN PHARMACOL DRUG DEV | 0 | 13% | 0.5% | 1 |
7 | SINHGAD TECH EDUC SOC | 0 | 10% | 0.5% | 1 |
8 | PDEA | 0 | 100% | 0.5% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000198639 | ETODOLAC//CAS 41340 25 4//DEXTRAN CARRIER |
2 | 0.0000141689 | NSAIDS//COXIBS//ROFECOXIB |
3 | 0.0000133556 | MELOXICAM//PIROXICAM//TENOXICAM |
4 | 0.0000128122 | OXAPROZIN//BRYONIA LACINIOSA//TIAPROFENIC ACID |
5 | 0.0000099607 | TENIDAP//TEPOXALIN//TENIDAP SODIUM |
6 | 0.0000089642 | DIAPHRAGM DISEASE//SMALL INTESTINAL INJURY//SMALL INTESTINAL DAMAGE |
7 | 0.0000089579 | HEXAMETHYLDISILAZANE TREATED SILICA//OCTADECYL MODIFIED SILICA//ABSORPTION ANALYSIS |
8 | 0.0000083601 | BENZYDAMINE//MED GEN SISTEMAT 3//CAS 132 69 4 |
9 | 0.0000080977 | SCAPULOCOSTAL SYNDROME//CABRINI HOSP PUBL HLTH PREVENT MED//HOSP NORWAY IMMUNOL RHEUMATOL |
10 | 0.0000080960 | CHIRAL INVERSION//DEXIBUPROFEN//FLOBUFEN |